Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward

See the article here:
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populations International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populations

Read more:
Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa

CAMBRIDGE, United Kingdom and SINGAPORE, April 22, 2025 (GLOBE NEWSWIRE) -- Cambridge’s DIOSynVax and Singapore’s ACM Biolabs will be jointly developing a next-generation universal bird flu vaccine with the potential for mucosal delivery to combat the next pandemic. This bilateral project is supported by Innovate UK1 and Enterprise Singapore2, as part of the UK-Singapore Collaborative R&D Call.

Link:
Cambridge’s DIOSynVax and Singapore’s ACM Biolabs to Advance Pandemic-Ready Universal Bird Flu Vaccine with International Support

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro’s deep learning and ML programs with Nebul’s high-performance computing (“HPC”) built on the latest platform to accelerate biomarker discovery and next-generation diagnostics.

Read the original here:
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

BANGKOK, April 22, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission on April 22, 2025 Eastern Time. The annual report can be accessed on the Company’s investor relations website at https://investors.newgenivf.com.

Originally posted here:
NewGen Filed 2024 Annual Report on Form 20-F

AGOURA HILLS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a biotechnology company focused on nanomedicine and RNA-based therapeutics, announced today that its Chairman and CEO, Dr. Vuong Trieu, will deliver a keynote presentation at the 21st Annual Congress of International Drug Discovery Science & Technology (IDDST-Europe), scheduled for June 18-20, 2025, in Stockholm, Sweden.

Continue reading here:
Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

Andrew Taylor will assume the role as EVP of Food & Beverage Biosolutions at Novonesis.

Link:
Andrew Taylor joins Novonesis’ Executive Leadership Team

MESA, Ariz., April 22, 2025 (GLOBE NEWSWIRE) -- Elite Clinical Network, a leading nationwide integrated clinical research site organization, has announced a strategic partnership with HealthyU Clinics, a digitally enabled primary care provider focused on delivering accessible, patient-centered healthcare.

Follow this link:
Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research

VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “Convertible Debentures”). The Convertible Debentures will be offered in units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “Offering”). The Company plans to use the proceeds of the Offering for general corporate purposes.

More:
Sirona Biochem Announces Debenture Financing

/ Not for distribution to U.S. news wire services or for dissemination in the United States /

Read more from the original source:
Digicann Ventures Provides Update Regarding Proposed RTO Transaction

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Read more from the original source:
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

-- Poster to be presented at OARSI World Congress on Osteoarthritis --BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the upcoming presentation of new 104-week data in support of its locally administered gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 Osteoarthritis Research Society International (OARSI) World Congress in Incheon, South Korea, April 24-27.

Read this article:
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe...

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

More:
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders.

Go here to see the original:
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering regenerative exosomes-based therapies for central nervous system injuries, is pleased to announce the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc. (“Exo-Top”), a wholly owned subsidiary of the Company, and as Vice President, Corporate Development at NurExone. Exo-Top is a U.S.-based GMP-compliant exosome manufacturing site and will be the pillar of the Company’s global supply chain and commercialization strategy.

Originally posted here:
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into...

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025.

Originally posted here:
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science

See the article here:
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and...

Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navify? Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome (ACS) in patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits. As EDs are typically one of the most crowded hospital units, leading to challenges to swiftly diagnose critical conditions, such as chest pain.4 This new algorithm was developed in collaboration with Universitätsklinikum Heidelberg.

See the article here:
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 -- VERAXA Biotech AG (“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, “Voyager” or the “SPAC”), announced today that they have entered into a definitive business combination agreement (the "Business Combination Agreement"). The proposed business combination (the "Business Combination") would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”

Continue reading here:
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a...

Five abstracts accepted for poster presentations

View original post here:
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025